Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
124I-A11 PSCA minibody is a radiopharmaceutical imaging agent designed for positron emission tomography (PET) of prostate cancer. It consists of a "minibody"—a genetically engineered antibody fragment comprising a single-chain variable fragment (scFv) linked to the CH3 domain of human IgG1—that specifically targets the Prostate Stem Cell Antigen (PSCA). PSCA is a cell surface glycoprotein highly overexpressed in prostate cancer, particularly in bone metastases and hormone-refractory cases. The minibody format (approximately 80 kDa) is optimized for rapid blood clearance and efficient tumor penetration compared to full-length antibodies, allowing for high-contrast imaging at earlier time points. Labeled with the positron emitter Iodine-124, this agent enables the non-invasive detection and localization of PSCA-positive lesions. It was primarily developed by researchers at UCLA and licensed to ImaginAb.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 124I-A11 PSCA minibody.